Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Biosensor Platform Monitors SARS-CoV-2 Antibody Durability

By LabMedica International staff writers
Posted on 20 Oct 2021
Low initial severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibody titers dropping to undetectable levels within months after infections have raised concerns about long-term immunity. More...


Seroprevalence studies have begun to show a larger extent of SARS-CoV-2 infections than initially reported because of the high prevalence of infected individuals with mild or no symptoms. However, lower SARS-CoV-2 IgG antibody levels have been reported in those with mild or no symptoms compared with those with severe COVID-19.

A team of Clinical Scientists collaborating with Weill Cornell Medicine (New York, NY, USA) developed a testing-on-a-probe “plus” panel (TOP-Plus) to include a newly developed avidity assay built into the previously described SARS-CoV-2 TOP assays that measured total antibody (TAb), surrogate neutralizing antibody (SNAb), IgM, and IgG on a versatile biosensor platform. TAb and SNAb levels were compared with avidity in previously infected individuals at 5.7 weeks and 30 weeks after infection in paired samples from 80 patients with coronavirus disease 2019 (COVID-19).

Sera from individuals vaccinated for SARS-CoV-2 were also evaluated for antibody avidity. The SARS-CoV-2 TAb and SNAb assays were used to measure plasma TAb and SNAb antibodies against SARS-CoV-2. Plasma samples were assayed on the fully automated Pylon 3-D analyzer (ET HealthCare, Palo Alto, CA, USA). Bio-layer interferometry measurements (Gator Bio, Palo Alto, CA, USA) were used to compare the avidity of 12 different purified COVID-19 antibodies with the TOP-Plus avidity assay.

The investigators reported that the newly designed avidity assay in this TOP panel correlated well with a reference Bio-Layer Interferometry avidity assay. The imprecision of the TOP avidity assay was <10%. Although TAb and neutralization activity (by SNAb) decreased between 5.7 and 30 weeks after infection, the antibody avidity increased significantly. Antibody avidity in 10 SARS-CoV-2 vaccinated individuals (median: 28 days after vaccination) was comparable to the measured antibody avidity in infected individuals (median: 26 days after infection). No cross-reactivity was displayed in sera from patients positive for HIV, Epstein–Barr virus, or rheumatoid factor.

The authors concluded that the TOP-Plus biosensor panel is a versatile sensing platform with high precision and an ability to measure SARS-CoV-2 TAb, SNAb, and individual IgG and IgM antibody levels along with the antibody’s long-term avidity. This combination of all-in-one testing will be a valuable asset in monitoring not only patients convalescing from COVID-19, but also the status of individuals’ COVID-19 vaccination response. The study was published in the September, 2021 issue of the journal Clinical Chemistry.

Related Links:
Weill Cornell Medicine
ET HealthCare
Gator Bio



New
Gold Member
Quality Control Material
iPLEX Pro Exome QC Panel
Serological Pipet Controller
PIPETBOY GENIUS
New
Staining System
RAL DIFF-QUIK
New
Hand-Held Immunofluorescence Analyzer
WS-Si1500
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.